Isis Pharmaceuticals calls all of 5½% convertibles due 2009

By Laura Lutz

Des Moines, April 12 - Isis Pharmaceuticals, Inc. plans to redeem all of its outstanding 5½% convertible subordinated notes due 2009 on May 10.

The notes are being voluntarily redeemed under the terms of the indenture.

In total, the company will pay about $82.1 million plus accrued interest of about $111,000 for the notes.

Isis will make its regular semi-annual interest payment on May 1.

Isis is a Carlsbad, Calif.-based drug maker focused on cardiovascular, metabolic, inflammatory and ocular diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.